Emerging studies suggest this peptide, a dual agonist targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , may represent a promising advancement for obesity treatment. Initial clinical tests have demonstrated impressive reductions in visceral tissue, potentially surpassing current body composition treatments. Howe… Read More